NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Biotechnology · USD

Evommune, Inc. (EVMN) Stock Analysis

Evommune, Inc. (EVMN) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

EVMN

$12.27

+$0.27 (+2.25%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVMN with… →

EVMN Key Statistics

As of Sep 4, 2026
Trading
Open
$11.87
Previous Close
$12.00
Day's Range
11.87–12.46
52-Week Range
10.47–33.20
Volume
249.10K
Valuation
Market Cap
$445.30M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
44.53
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.09
Financials (FY)
Revenue (FY)
$13.00M
Net Income (FY)
−$68.87M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
36.29M
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
796.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EVMN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.33%
2025 (partial year)−15.37%

As of September 4, 2026.

EVMN Valuation vs Biotechnology Median

Median of 656 stocks
MetricEVMNBiotechnology medianvs median
P/S ratio44.5315.26192% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Evommune, Inc. (EVMN) carries a market capitalisation of $445.30M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 48 employees.

The 52-week range on file runs from $10.47 to $33.20. EVMN last closed at $12.27 on September 4, 2026. That is +$0.27 (+2.25%) against the previous close. The latest close sits 17.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $13.00M. The same year closed with a net loss of $68.87M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −12.09.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 44.53 times revenue. On price-to-sales that is 191.74% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The stored price history starts on November 6, 2025, and the total return since then is −39.35%.

Growth & Income

The record shows no dividend for EVMN.

So far in 2026 the price is −28.33%.

Peer Comparison

Evommune, Inc. (EVMN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evommune, Inc. EVMN $445.30M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Evommune, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Visit website →